Point Roberts, WA - January 6, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Dendreon Corporation (NasdaqGS: DNDN). The stock is on the move again trading through yesterday's highs and is currently trading at $11.99, up 1.37 (12.90%) 1:40PM EST with a day's high of $12.18.
The stock closed up at $10.57, up 2.97 (39.08%) in yesterday�s trading session following news of revenue growth.
The Company announced yesterday revenue for the fourth quarter ended December 31, 2011, with gross product revenue of approximately $82 million, a 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010.Dendreon also reported full-year gross revenues from PROVENGE� (sipuleucel-T) sales of approximately $228 million.
About Dendreon (NasdaqGS: DNDN)
Get biotech news and stock alerts
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - www.Investorideas.com